The Salk approach, tested in a mouse model, points to cheaper and more effective treatments for humans
For most people with hemophilia B, whose bodies can’t properly form blood clots, constant injections to replenish their clotting factors are a way of life. But now, Salk researchers have demonstrated in mice that hemophilia B can be treated for life with one single injection containing disease-free liver cells that can produce their missing clotting factor. The finding, published in the journal Cell Reports on May 1, 2018, could drastically change what it means to be diagnosed with hemophilia B, and could pave the way toward similar treatments for other, related genetic disorders.
Hemophilia B is caused by defects in the gene for a protein called clotting factor IX (FIX). Hemophiliacs may make reduced amounts of the protein, or lack a functional version altogether, leading to life-threatening delays in blood clotting. Currently, patients are treated with injections—as often as a few times a week—containing FIX made in animal cells and then purified. But the approach is expensive, time-consuming and can become less effective over time.
Recently, Salk scientists developed a new approach, treating mice genetically engineered to have hemophilia B with strands of messenger RNA encoding the FIX gene. Like the standard treatment, however, this required repeat injections each time levels of the messenger RNA ran low. So the scientists wanted to try a more permanent approach: transplanting healthy liver cells, capable of producing FIX, into patients.
“The appeal of a cell-based approach is that you minimize the number of treatments that a patient needs,” says Suvasini Ramaswamy, a former Salk research associate in the Verma lab and first author of the new paper. “Rather than constant injections, you can do this in one shot.”
Since donor livers are often in short-supply, the researchers instead turned to stem-cell strategies to produce the healthy liver cells. They collected blood samples from two human patients with severe hemophilia B, who are unable to produce FIX. Then, in the lab, they reprogrammed the cells into induced pluripotent stem cells (iPSCs), which have the capability to turn into many other cell types, including liver. Using CRISPR/Cas9, a tool that can alter genes, they then repaired the mutations in each patient’s FIX gene. Finally, they coaxed those repaired cells to develop into liver precursor cells called hepatocyte-like cells (HLCs) and transplanted them into mice with hemophilia B.
Rather than perform surgery on hemophilic mice—a risky undertaking when their blood can’t always clot—the team transplanted the HLCs through the spleen to distribute the cells uniformly in the liver.
Not only did the new HLCs produce FIX, but they produced enough of the protein to allow the mice to form normal blood clots, and the cells continued to survive—and produce FIX—for at least a year after the transplantation.
In people with hemophilia, using their own cells to generate healthy HLCs, then transplanting them back into their bodies, could help avoid the immune complications that often accompany cell therapies. But more work is needed to translate the findings to the clinic.
“A lot of things have to happen before this can go into humans,” says Ramaswamy.
Already, she adds, the work demonstrates the value in combining stem-cell reprogramming and new gene-modifying approaches to treat genetic diseases.
The Latest on: Hemophilia B
via Google News
The Latest on: Hemophilia B
- Explore Hemophilia A treatment market forecasts by 2022 on September 18, 2018 at 3:41 am
Hemophilia A is about four times as common as hemophilia B. The number of people with hemophilia in the United States is estimated to be about 20,000 individuals. Approximately 75% of people with hemo... […]
- Global hemophilia market forecast to 2021 made available by top research firm on September 11, 2018 at 8:20 pm
It is classified into hemophilia A, hemophilia B, hemophilia C, and hemophilia with inhibitors. Access a copy of this “Global Hemophilia Market: Industry Analysis & Outlook (2017-2021)” research repor... […]
- Global Hemophilia Epidemiology Forecast to 2025 - ResearchAndMarkets.com on September 11, 2018 at 4:22 am
DUBLIN--(BUSINESS WIRE)--Sep 11, 2018--The "Hemophilia - Epidemiology Forecast to 2025" report has been added to ResearchAndMarkets.com's offering. Hemophilia - Epidemiology Forecast To 2025 provides ... […]
- Global Hemophilia B Market Insights, Epidemiology and Market Forecast 2015-2017 & 2025 - ResearchAndMarkets.com on September 11, 2018 at 4:12 am
DUBLIN--(BUSINESS WIRE)--Sep 11, 2018--The "Hemophilia B - Market Insights, Epidemiology and Market Forecast - 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. Hemophilia B - ... […]
- Global Hemophilia B Market Insights, Epidemiology and Market Forecast 2015-2017 & 2025 - ResearchAndMarkets.com on September 11, 2018 at 12:48 am
The "Hemophilia B - Market Insights, Epidemiology and Market Forecast - 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. Hemophilia B - Market Insights, Epidemiology and Marke... […]
- Catalyst Biosciences: Highly Attractive Hemophilia Pipeline With Upcoming Catalysts, Yet Still Trading At Cash Value on September 7, 2018 at 3:06 am
... A have abnormalities in regards to clotting factor FVIII whereas patients with hemophilia B have abnormalities in regards to clotting factor IX. Treatments for hemophilia are mostly based ... […]
- With success in gene therapy trials, hemophilia may no longer be a 'lifelong thing' on September 6, 2018 at 9:14 pm
A handful of biotech companies are rushing to get their gene therapies to market. Spark, with gene therapy for hemophilia B, and BioMarin, with a treatment for hemophilia A, are starting final-phase c... […]
- Spark's Gene Therapy For Hemophilia B Looks To Change Up The Game on September 2, 2018 at 12:01 am
Spark Therapeutics posts positive phase 1/2 results treating patients with Hemophilia B using SPK-9001. Pfizer is expected to lead the rest of the development for the Hemophilia B candidate SPK-9001 b... […]
via Bing News